{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:25:43Z","timestamp":1758817543694,"version":"3.38.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ejps.2025.107023","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:35:43Z","timestamp":1737448543000},"page":"107023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A new population pharmacokinetic model for dosing optimization of zonisamide in patients with refractory epilepsy"],"prefix":"10.1016","volume":"207","author":[{"given":"Rui","family":"Silva","sequence":"first","affiliation":[]},{"given":"Helena","family":"Colom","sequence":"additional","affiliation":[]},{"given":"Anabela","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Carona","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Sales","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Santana","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107023_bib0010","doi-asserted-by":"crossref","unstructured":"Baulac, M.; Leppik, I.E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. 2007.","DOI":"10.1016\/j.eplepsyres.2007.04.007"},{"key":"10.1016\/j.ejps.2025.107023_bib0051","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2025.107023_bib0056","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2025.107023_bib0002","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1586\/14737175.4.6.935","article-title":"Newer antiepileptic agent with multiple mechanisms of action","volume":"4","author":"Biton","year":"2004","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejps.2025.107023_bib0003","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","article-title":"Clinical pharmacology and mechanism of action of zonisamide","volume":"30","author":"Biton","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejps.2025.107023_bib0013","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ejps.2025.107023_bib0023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12016","article-title":"Zonisamide: its pharmacology, efficacy and safety in clinical trials","volume":"126","author":"Brodie","year":"2012","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ejps.2025.107023_bib0009","doi-asserted-by":"crossref","unstructured":"Brodie, M.J. Zonisamide as adjunctive therapy for refractory partial seizures. 2006, 11\u201316.","DOI":"10.1016\/j.eplepsyres.2005.11.005"},{"key":"10.1016\/j.ejps.2025.107023_bib0019","article-title":"Zonisamide for essential tremor","volume":"2017","author":"Bruno","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejps.2025.107023_bib0021","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/WNF.0000000000000208","article-title":"The use of zonisamide for the treatment of psychiatric disorders: a systematic review","volume":"40","author":"Buoli","year":"2017","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejps.2025.107023_bib0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejps.2025.107023_bib0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality ? Lessons from the past and a roadmap for the future This article has been accepted for publication and undergone full peer review but has not been through the copyediting, ty","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107023_bib0041","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1528-1157.1997.tb01142.x","article-title":"Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects","volume":"38","author":"Deckers","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2025.107023_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176344552","article-title":"Bootstrap methods: another look at the jackknife","volume":"7","author":"Efron","year":"1979","journal-title":"Ann. Stat."},{"key":"10.1016\/j.ejps.2025.107023_bib0046","first-page":"1845","article-title":"Population pharmacokinetic modeling: the importance of informative graphics","volume":"12","author":"Ette","year":"1995","journal-title":"Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107023_bib0049","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270003253624","article-title":"Model appropriateness and population pharmacokinetic modeling","volume":"43","author":"Ette","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107023_bib0048","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107023_bib0005","unstructured":"European medicines agency ZONEGRAN: summary of product characteristics."},{"key":"10.1016\/j.ejps.2025.107023_bib0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eplepsyres.2013.04.009","article-title":"Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects","volume":"106","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2025.107023_bib0033","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1248\/bpb.27.2000","article-title":"Influence of coadministered antiepileptic drugs on serum zonisamide concentrations in epileptic patients: quantitative analysis based on a suitable transforming factor","volume":"27","author":"Fukuoka","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2025.107023_bib0007","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200210","article-title":"A comprehensive, updated review for the clinician","volume":"14","author":"Gidal","year":"2024","journal-title":"Neurol. Clin. Pract"},{"key":"10.1016\/j.ejps.2025.107023_bib0015","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1007\/s10072-021-05550-2","article-title":"Zonisamide in Parkinson's disease: a current update","volume":"42","author":"Goel","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejps.2025.107023_bib0042","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4155\/bio-2017-0199","article-title":"Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma","volume":"10","author":"Gon\u00e7alves","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ejps.2025.107023_bib0036","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1248\/bpb.17.323","article-title":"Population analysis of the dose-dependent pharmacokinetics of Zonisamide in epileptic patients","volume":"14","author":"Hashimoto","year":"1994","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2025.107023_bib0024","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1517\/14656566.2011.622268","article-title":"Zonisamide in the treatment of epilepsy","volume":"12","author":"Holder","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejps.2025.107023_bib0029","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update","volume":"52","author":"Italiano","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107023_bib0047","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2025.107023_bib0027","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1248\/cpb.40.193","article-title":"Factors influencing serum concentration of Zonisamide in epileptic patients","volume":"40","author":"Kimura","year":"1992","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejps.2025.107023_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107023_bib0053","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring","volume":"18","author":"Landmark","year":"2016","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.ejps.2025.107023_bib0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.seizure.2004.04.016","article-title":"Chemistry, mechanism of action, and pharmacokinetics","volume":"13","author":"Leppik","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.ejps.2025.107023_bib0032","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1177\/0091270004268045","article-title":"Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy","volume":"44","author":"Levy","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107023_bib0016","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3233\/JAD-161068","article-title":"Combination therapy with Zonisamide and Antiparkinson drugs for Parkinson's disease: a meta-analysis","volume":"56","author":"Matsunaga","year":"2017","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.ejps.2025.107023_bib0057","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0000000000000138","article-title":"Could adult European pharmacoresistant epilepsy patients be treated with higher doses of zonisamide?","volume":"39","author":"Miro","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejps.2025.107023_bib0022","article-title":"Zonisamide for neuropathic pain in adults","volume":"2014","author":"Moore","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejps.2025.107023_bib0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/DDDT.S43612","article-title":"Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults","volume":"7","author":"Mula","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2025.107023_bib0017","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jagp.2021.07.002","article-title":"Long-term efficacy and safety of zonisamide for treatment of parkinsonism in patients with dementia with Lewy bodies: an open-label extension of a phase three randomized controlled trial","volume":"30","author":"Odawara","year":"2022","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejps.2025.107023_bib0037","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/FTD.0b013e31817d842a","article-title":"Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance","volume":"30","author":"Okada","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2025.107023_bib0044","doi-asserted-by":"crossref","unstructured":"Olofsen, E.; Dahan, A. Using Akaike \u2019 s information theoretic criterion in mixed-effects modeling of pharmacokinetic data : a simulation study [version 2 ; referees : 1 approved, 1 approved with reservations, 1 not approved] Referee Status : 2015, 1\u201316.","DOI":"10.12688\/f1000research.2-71.v3"},{"key":"10.1016\/j.ejps.2025.107023_bib0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/pharmaceutics14122731","article-title":"Model-informed precision dosing (MIPD)","volume":"14","author":"P\u00e9rez-Blanco","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107023_bib0039","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1111\/bcp.13647","article-title":"comparison of the cockcroft\u2013gault, MDRD and CKD-EPI equations for estimating ganciclovir clearance","volume":"84","author":"Palacio-Lacambra","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107023_bib0026","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2025.107023_bib0006","doi-asserted-by":"crossref","unstructured":"Patsalos, P.N.; Spencer, E.P.; Berry, D.J. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update; 2018; Vol. 40;.","DOI":"10.1097\/FTD.0000000000000546"},{"key":"10.1016\/j.ejps.2025.107023_bib0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-199631010-00003","article-title":"The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine","volume":"31","author":"Perucca","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107023_bib0038","doi-asserted-by":"crossref","first-page":"362","DOI":"10.5414\/CP202104","article-title":"Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers","volume":"54","author":"Qiu","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107023_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.06.008","article-title":"Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients","volume":"62","author":"Ragueneau-Majlessi","year":"2004","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2025.107023_bib0020","doi-asserted-by":"crossref","DOI":"10.2165\/11538180-000000000-00000","article-title":"Pharmacological management of essential tremor","author":"Sadeghi","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2025.107023_bib0045","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2025.107023_bib0031","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1248\/bpb.19.1090","article-title":"The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs","volume":"19","author":"Shinoda","year":"1996","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ejps.2025.107023_bib0008","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1528-1167.2007.00983.x","article-title":"Pharmacokinetics and drug interactions with zonisamide","volume":"48","author":"Sills","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2025.107023_bib0018","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/DDDT.S240865","article-title":"The application of zonisamide to patients suffering from dementia with lewy bodies: emerging clinical data","volume":"15","author":"Tousi","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2025.107023_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2014.04.010","article-title":"Zonisamide for refractory juvenile absence epilepsy","author":"Velizarova","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2025.107023_bib0054","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0034-1387815","article-title":"Pharmacokinetics, efficacy, and adverse events in children with epilepsy","volume":"45","author":"Wallander","year":"2014","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ejps.2025.107023_bib0040","unstructured":"WHO ATC\/DDD Index 2021 Available online: https:\/\/www.whocc.no\/atc_ddd_index\/(accessed on Jan 30, 2023)."},{"key":"10.1016\/j.ejps.2025.107023_bib0052","unstructured":"WHO Body Mass Index Available online: http:\/\/www.euro.who.int\/en\/health-topics\/disease-prevention\/nutrition\/a-healthy-lifestyle\/body-mass-index-bmi (accessed on Oct 14, 2023)."},{"key":"10.1016\/j.ejps.2025.107023_bib0004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/nedt.2006.2.3.269","article-title":"Zonisamide - a review of experience and use in partial seizures","volume":"2","author":"Wilfong","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ejps.2025.107023_bib0043","doi-asserted-by":"crossref","unstructured":"Yamaoka, K. Application of Akaike \u2019 s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. 1978, 6, 165\u2013175.","DOI":"10.1007\/BF01117450"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T19:46:20Z","timestamp":1740685580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":57,"alternative-id":["S0928098725000223"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107023","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new population pharmacokinetic model for dosing optimization of zonisamide in patients with refractory epilepsy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107023"}}